Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
|Articles|August 10, 2010

BioClinica Partners with Axio Research Corporation and Beardsworth Consulting Group

BioClinica

announced it has created strategic partnerships with two privately held clinical research organizations (CROs),

Axio Research Corporation

and

Beardsworth Consulting Group, Inc.

Both alliances strengthen the

BioClinica Certified Partner Program

and provide customers with additional support in complex therapeutic areas of study and data monitoring and management.
 
Mark Weinstein, CEO of BioClinica, Inc. "Both Axio Research and Beardsworth match the quality and industry leadership of all partners recognized by the BioClinica Certified Partner Program, and we are pleased to offer our customers this expanded support. Our certified partners now represent a collective experience of over 1000 trials in more than 6000 sites across 52 countries."
 
Since 1979, Axio Research has provided data management, statistical and medical writing services for industry, government, and academic sponsors in the clinical research field. Based in Seattle, Washington, the company also provides clinical trial design and clinical events committee support services, and serves as the independent statistical center for Data Monitoring Committees.
 
Based in Flemington, New Jersey, Beardsworth is a specialty CRO in Oncology, delivering a broad range of clinical research services to pharmaceutical and biotechnology companies. Since 1986, the company has focused on complicated trials in complex therapeutic areas, utilizing an internal paper-based data management system.  


Related to this article

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.
© Grispb - © Grispb - stock.adobe.com
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.